Article
Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073).
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology - 1 Jun 2005
Descamps Diane, Joly Véronique, Flandre Philippe, Peytavin Gilles, Meiffrédy Vincent, Delarue Séverine, Lastère Stéphane, Aboulker Jean-Pierre, Yeni Patrick, Brun-Vézinet Françoise
Abstract excerpt
BACKGROUND: Different studies have shown that most patients failing a first-line treatment containing a protease-inhibitor (PI) had low PI plasma levels and no PI-related resistance mutations. NOVAVIR was a randomized trial comparing stavudine/lamivudine/indinavir (d4T/3TC/IDV) and zidovudine/lamivudine/indinavir (AZT/3TC/IDV) in patients pretreated with AZT, didanosine (ddI) and/or zalcitabine (ddC) but naive...
Topics
- Amino Acid Substitution
- Drug Resistance, Viral
- HIV
- HIV Infections
- HIV Protease
- HIV Protease Inhibitors
- HIV Reverse Transcriptase
- Humans
- Indinavir